The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by RFA-CA-27-005.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,038,411 in first-year total cost, median $999,063.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-D (A1)]5
Most frequent institutions
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
- BRIGHAM AND WOMEN'S HOSPITAL1
- DUKE UNIVERSITY1
- MAYO CLINIC ROCHESTER1
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Center of Innovation for Brain Tumor Therapeutics1U19CA264362-01 | BINDRA, RANJITGALANIS, EVANTHIAOMURO, ANTONIO MSARKARIA, JANN N. | MAYO CLINIC ROCHESTER, MN | $1,243,819 | ZCA1 |
| 2021 | Harvard/Stanford GTN Program: Novel targeted therapeutics for glioblastoma1U19CA264504-01 | BATCHELOR, TRACY T | BRIGHAM AND WOMEN'S HOSPITAL, MA | $1,014,545 | ZCA1 |
| 2021 | Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability1U19CA264512-01 | BADIE, BEHNAMPORTNOW, JANA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $999,063 | ZCA1 |
| 2021 | 6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration1U19CA264385-01 | ASHLEY, DAVID M.SHAY, JERRY WILLIAM | DUKE UNIVERSITY, NC | $895,748 | ZCA1 |
| 2021 | Advancing treatment and understanding of immunotherapy in glioblastoma1U19CA264338-01 | BUTOWSKI, NICHOLAS ASTUPP, ROGER | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $885,236 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.